Curasight Engages Investors at Major Healthcare Conference
COPENHAGEN, Denmark / Curasight A/S, also known as Curasight (CPH: CURAS), is a clinical-stage theranostic company devoted to diagnosing and treating various cancers. Notably, CEO Ulrich Krasilnikoff and CMO Professor Andreas Kjær are slated to participate in significant discussions in San Francisco during the J.P. Morgan Healthcare Conference. This prestigious event is a vital platform for healthcare leaders to network and share critical insights.
Throughout the conference week, the management team from Curasight is looking forward to connecting with investors and influential figures in the healthcare sector. These meetings aim to present updates on the company's latest clinical developments, particularly focusing on the initiation of a Phase 1 trial involving uTREAT® targeting aggressive brain cancer, as well as the ongoing Phase 2 initiative of uTRACE® within prostate cancer, in collaboration with Curium Inc.
Enhancing Cancer Treatment with Innovative Technology
Curasight’s unique uPAR theranostic platform represents a significant advancement in cancer care. This integrated system includes two vital technologies: uTRACE and uTREAT. Each technology is strategically focused on targeting the uPAR receptor, which plays a crucial role in cancer progression.
uTRACE is designed to enhance diagnostic imaging, providing healthcare professionals with sensitive tools for early detection. Concurrently, uTREAT is focused on delivering a targeted radiopharmaceutical solution, creating a holistic approach to cancer diagnosis and treatment.
Commitment to Improving Cancer Care
The ambition behind Curasight’s development of both uTRACE and uTREAT centers on refining methods for diagnosing and treating types of cancer that exhibit uPAR expression. This innovation seeks to offer a more precise and effective therapeutic option for patients battling such aggressive forms of cancer.
By harnessing cutting-edge technology, Curasight aims to significantly alter the landscape of cancer treatment, enhancing both the efficiency of diagnosis and the effectiveness of treatment modalities.
About Curasight
Curasight is dedicated to advancing the field of oncological treatments and diagnostics. Their passionate approach to metastatic cancer management underscores their mission to innovate and improve patient outcomes. The ongoing trials and technological developments reflect Curasight's commitment to bringing transformative solutions to the healthcare industry.
For inquiries regarding Curasight and its initiatives, please reach out to:
Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
Frequently Asked Questions
What is Curasight’s focus as a company?
Curasight focuses on diagnosing and treating cancers using its innovative uPAR theranostic platform.
Who is representing Curasight at the J.P. Morgan Healthcare Conference?
CEO Ulrich Krasilnikoff and CMO Prof. Andreas Kjær will represent Curasight at the conference.
What are uTRACE and uTREAT?
uTRACE is a diagnostic tool for sensitive imaging, while uTREAT is a targeted radiopharmaceutical for treatment.
What type of trials is Curasight currently conducting?
Curasight is currently conducting a Phase 1 trial for uTREAT in aggressive brain cancer and a Phase 2 trial for uTRACE in prostate cancer.
How can interested parties contact Curasight?
Interested individuals can contact Ulrich Krasilnikoff, CEO, at +45 22 83 01 60 for more information.